ISO 21973: A Leap Forward in Standardizing the Regenerative Medicine Supply Chain
CRYOPORT SPONSORED CONTENT

ISO 21973: A Leap Forward in Standardizing the Regenerative Medicine Supply Chain

In June 2020, the ISO/TC 276 Biotechnology Technical Committee defined a new standard for the transportation of cells for therapeutic use. The power of the new ISO 21973 standard is its development of a clear path to optimal efficiency and risk mitigation. As this new industry expands and matures, with cell and gene therapies being used for an ever-increasing list of indications, reducing risk in the supply chain will become crucial in ensuring that these drugs arrive on time, in the best condition, at the most important destination – the waiting patient.

Download the Document

    * denotes a required field

    Please fill out the information below. If you are already registered, and this information will be filled out for you.

  • Please enter your first and last name.

  • Please enter the name of the company or institution you work at.

  • Please enter your mailing address.

  • Please enter the e-mail address you would like to be contacted at.

  • Please enter the phone number you would like to be contacted at.

    • By submitting this form, you consent to American Pharmaceutical Review storing your email address and contact information and transmitting your contact information to the content sponsor. You may request to be removed at any time.